Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 36 | 2026 | 974 | 3.610 |
Why?
|
| Schools, Medical | 5 | 2018 | 144 | 2.210 |
Why?
|
| Students, Medical | 10 | 2022 | 455 | 2.110 |
Why?
|
| China | 23 | 2026 | 264 | 2.010 |
Why?
|
| Anti-HIV Agents | 11 | 2026 | 199 | 1.650 |
Why?
|
| Education, Medical | 6 | 2019 | 252 | 1.510 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2019 | 189 | 1.390 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2026 | 186 | 1.200 |
Why?
|
| Curriculum | 8 | 2019 | 615 | 1.160 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 682 | 0.920 |
Why?
|
| Immunocompromised Host | 2 | 2023 | 147 | 0.830 |
Why?
|
| Homosexuality, Male | 6 | 2026 | 332 | 0.810 |
Why?
|
| Women's Health | 2 | 2019 | 109 | 0.720 |
Why?
|
| Medication Adherence | 4 | 2026 | 122 | 0.690 |
Why?
|
| Teaching | 3 | 2017 | 154 | 0.690 |
Why?
|
| Internship and Residency | 4 | 2019 | 1134 | 0.680 |
Why?
|
| Anti-Retroviral Agents | 5 | 2023 | 35 | 0.670 |
Why?
|
| Educational Measurement | 4 | 2019 | 246 | 0.660 |
Why?
|
| Transplant Recipients | 1 | 2021 | 157 | 0.620 |
Why?
|
| International Cooperation | 2 | 2013 | 134 | 0.600 |
Why?
|
| HIV-1 | 5 | 2007 | 182 | 0.570 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 777 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2003 | 74 | 0.560 |
Why?
|
| Ethics, Medical | 2 | 2017 | 312 | 0.540 |
Why?
|
| Reference Standards | 1 | 2018 | 150 | 0.530 |
Why?
|
| Neurosciences | 2 | 2016 | 53 | 0.530 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2017 | 9 | 0.530 |
Why?
|
| Geriatrics | 1 | 2018 | 72 | 0.520 |
Why?
|
| Neurologists | 1 | 2016 | 8 | 0.510 |
Why?
|
| Humans | 60 | 2026 | 96127 | 0.500 |
Why?
|
| Neurosurgeons | 1 | 2016 | 45 | 0.500 |
Why?
|
| Health Care Reform | 1 | 2017 | 86 | 0.480 |
Why?
|
| Sexual and Gender Minorities | 3 | 2026 | 250 | 0.480 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2019 | 80 | 0.480 |
Why?
|
| Telemedicine | 3 | 2026 | 229 | 0.480 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 2860 | 0.470 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2005 | 23 | 0.460 |
Why?
|
| Career Choice | 1 | 2016 | 163 | 0.450 |
Why?
|
| Histology | 1 | 2014 | 4 | 0.450 |
Why?
|
| Physiology | 1 | 2014 | 18 | 0.450 |
Why?
|
| Health Communication | 1 | 2014 | 14 | 0.430 |
Why?
|
| Internal Medicine | 1 | 2018 | 371 | 0.420 |
Why?
|
| Mental Health Services | 2 | 2014 | 78 | 0.420 |
Why?
|
| Health Services Accessibility | 3 | 2011 | 491 | 0.410 |
Why?
|
| Cross Infection | 1 | 2015 | 159 | 0.400 |
Why?
|
| Communication | 2 | 2014 | 477 | 0.400 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 77 | 0.400 |
Why?
|
| Competency-Based Education | 3 | 2019 | 38 | 0.390 |
Why?
|
| Drugs, Generic | 1 | 2013 | 21 | 0.390 |
Why?
|
| Clostridium Infections | 1 | 2015 | 128 | 0.380 |
Why?
|
| Male | 29 | 2026 | 45870 | 0.380 |
Why?
|
| Adult | 24 | 2026 | 28718 | 0.380 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 79 | 0.380 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 1874 | 0.380 |
Why?
|
| Depression | 2 | 2014 | 560 | 0.370 |
Why?
|
| Delivery of Health Care | 3 | 2011 | 469 | 0.360 |
Why?
|
| Health Care Surveys | 3 | 2017 | 295 | 0.350 |
Why?
|
| HIV Protease Inhibitors | 4 | 2007 | 21 | 0.350 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 378 | 0.340 |
Why?
|
| Faculty, Medical | 3 | 2019 | 207 | 0.340 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 635 | 0.310 |
Why?
|
| Female | 25 | 2024 | 50063 | 0.310 |
Why?
|
| Young Adult | 10 | 2026 | 7025 | 0.300 |
Why?
|
| Antiviral Agents | 3 | 2023 | 504 | 0.280 |
Why?
|
| Preventive Health Services | 1 | 2008 | 39 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 569 | 0.280 |
Why?
|
| Clinical Competence | 4 | 2018 | 854 | 0.270 |
Why?
|
| Mentors | 2 | 2018 | 101 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2024 | 361 | 0.240 |
Why?
|
| Patient Compliance | 4 | 2003 | 239 | 0.240 |
Why?
|
| Middle Aged | 16 | 2026 | 28363 | 0.240 |
Why?
|
| Neoplasms | 1 | 2021 | 3250 | 0.230 |
Why?
|
| Hospitalization | 2 | 2021 | 943 | 0.230 |
Why?
|
| Health Education | 2 | 2012 | 107 | 0.230 |
Why?
|
| Sulfonamides | 1 | 2007 | 338 | 0.220 |
Why?
|
| Drug Therapy, Combination | 6 | 2007 | 813 | 0.210 |
Why?
|
| Facial Neuralgia | 1 | 2024 | 1 | 0.210 |
Why?
|
| Peer Group | 1 | 2025 | 94 | 0.210 |
Why?
|
| Developing Countries | 1 | 2004 | 91 | 0.210 |
Why?
|
| Global Health | 1 | 2005 | 213 | 0.210 |
Why?
|
| Cell Phone | 1 | 2023 | 38 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2025 | 386 | 0.200 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 92 | 0.200 |
Why?
|
| Adolescent | 8 | 2021 | 9896 | 0.200 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 436 | 0.190 |
Why?
|
| Poverty | 1 | 2004 | 196 | 0.190 |
Why?
|
| Indinavir | 1 | 2002 | 3 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2024 | 323 | 0.190 |
Why?
|
| Crowdsourcing | 1 | 2022 | 12 | 0.190 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 70 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 180 | 0.190 |
Why?
|
| Mobile Applications | 1 | 2023 | 79 | 0.190 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 514 | 0.180 |
Why?
|
| Emtricitabine | 3 | 2026 | 10 | 0.170 |
Why?
|
| Tenofovir | 3 | 2026 | 16 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 481 | 0.170 |
Why?
|
| Social Support | 1 | 2002 | 239 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2019 | 8 | 0.160 |
Why?
|
| Cryptococcosis | 1 | 2019 | 11 | 0.160 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 60 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2000 | 66 | 0.150 |
Why?
|
| Viral Load | 5 | 2007 | 164 | 0.150 |
Why?
|
| Licensure, Medical | 1 | 2019 | 22 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2019 | 37 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2022 | 10286 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2002 | 391 | 0.140 |
Why?
|
| Prevalence | 3 | 2015 | 1349 | 0.140 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 2 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 361 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 424 | 0.140 |
Why?
|
| Gynecology | 1 | 2019 | 130 | 0.140 |
Why?
|
| Chicago | 5 | 2002 | 1503 | 0.140 |
Why?
|
| Capacity Building | 1 | 2017 | 12 | 0.130 |
Why?
|
| Hospice Care | 1 | 2017 | 43 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2017 | 40 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7232 | 0.130 |
Why?
|
| Universities | 1 | 2018 | 154 | 0.130 |
Why?
|
| Zidovudine | 1 | 1996 | 16 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2025 | 3107 | 0.130 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 14 | 0.120 |
Why?
|
| Models, Organizational | 1 | 1996 | 48 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 145 | 0.120 |
Why?
|
| Risk Factors | 4 | 2014 | 5960 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 381 | 0.120 |
Why?
|
| Education, Public Health Professional | 1 | 2015 | 2 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 66 | 0.120 |
Why?
|
| Palliative Care | 1 | 2017 | 273 | 0.120 |
Why?
|
| United States | 4 | 2019 | 7767 | 0.110 |
Why?
|
| Learning | 1 | 2018 | 305 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 404 | 0.110 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 9 | 0.110 |
Why?
|
| Self-Assessment | 1 | 2014 | 48 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 54 | 0.110 |
Why?
|
| Aged | 4 | 2021 | 20964 | 0.100 |
Why?
|
| Specialization | 1 | 2014 | 69 | 0.100 |
Why?
|
| Syphilis | 1 | 1994 | 36 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 245 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1178 | 0.100 |
Why?
|
| Neurology | 1 | 2014 | 83 | 0.100 |
Why?
|
| Focus Groups | 1 | 2014 | 189 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2026 | 819 | 0.090 |
Why?
|
| Patient Medication Knowledge | 1 | 2012 | 1 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 441 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 111 | 0.090 |
Why?
|
| Attitude | 1 | 2013 | 137 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2016 | 502 | 0.090 |
Why?
|
| Directive Counseling | 1 | 2012 | 35 | 0.090 |
Why?
|
| Psychiatry | 1 | 2013 | 90 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 92 | 0.090 |
Why?
|
| Physician's Role | 2 | 1996 | 186 | 0.090 |
Why?
|
| Social Stigma | 1 | 2012 | 86 | 0.090 |
Why?
|
| HIV Seropositivity | 2 | 1988 | 53 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2014 | 815 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 653 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2023 | 938 | 0.080 |
Why?
|
| Child | 4 | 2004 | 7626 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2024 | 376 | 0.080 |
Why?
|
| Drug Resistance, Viral | 2 | 2007 | 48 | 0.080 |
Why?
|
| Urban Population | 2 | 2002 | 240 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1175 | 0.070 |
Why?
|
| Hypertension | 1 | 2014 | 777 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 935 | 0.070 |
Why?
|
| Role | 1 | 1988 | 11 | 0.070 |
Why?
|
| Darunavir | 1 | 2007 | 1 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2019 | 9173 | 0.060 |
Why?
|
| Program Development | 2 | 2018 | 136 | 0.060 |
Why?
|
| Physician Assistants | 2 | 2017 | 28 | 0.060 |
Why?
|
| Nurse Practitioners | 2 | 2017 | 34 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2004 | 74 | 0.060 |
Why?
|
| Text Messaging | 1 | 2026 | 35 | 0.060 |
Why?
|
| Telephone | 1 | 2005 | 36 | 0.060 |
Why?
|
| Foster Home Care | 1 | 2004 | 8 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2004 | 6 | 0.050 |
Why?
|
| Ritonavir | 1 | 2004 | 13 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2004 | 44 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 1096 | 0.050 |
Why?
|
| Case Management | 1 | 2002 | 29 | 0.050 |
Why?
|
| Transportation of Patients | 1 | 2002 | 35 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2012 | 36 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2002 | 15 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 153 | 0.050 |
Why?
|
| Brazil | 2 | 2012 | 82 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 31 | 0.050 |
Why?
|
| Australia | 2 | 2012 | 124 | 0.050 |
Why?
|
| Health Personnel | 1 | 2024 | 241 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 85 | 0.040 |
Why?
|
| Europe | 2 | 2012 | 349 | 0.040 |
Why?
|
| Mental Health | 1 | 2002 | 202 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 1807 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2019 | 6 | 0.040 |
Why?
|
| Fluconazole | 1 | 2019 | 11 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2019 | 37 | 0.040 |
Why?
|
| Meningitis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2002 | 307 | 0.040 |
Why?
|
| Social Class | 1 | 2000 | 145 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2019 | 126 | 0.040 |
Why?
|
| Physicians | 2 | 2017 | 707 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 688 | 0.030 |
Why?
|
| Group Processes | 1 | 2017 | 31 | 0.030 |
Why?
|
| Formative Feedback | 1 | 2017 | 15 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2017 | 22 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 128 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 169 | 0.030 |
Why?
|
| Survival Rate | 1 | 2000 | 1986 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1994 | 24 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 1994 | 57 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 5585 | 0.020 |
Why?
|
| Cote d'Ivoire | 1 | 2012 | 2 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 60 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 202 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 107 | 0.020 |
Why?
|
| Prejudice | 1 | 2012 | 49 | 0.020 |
Why?
|
| Social Isolation | 1 | 2012 | 70 | 0.020 |
Why?
|
| Pregnancy | 2 | 1996 | 3240 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1996 | 2614 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3363 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1996 | 3974 | 0.020 |
Why?
|
| Mass Screening | 1 | 1994 | 710 | 0.020 |
Why?
|
| Coccidiosis | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cryptosporidiosis | 1 | 1987 | 6 | 0.020 |
Why?
|
| Confidentiality | 1 | 1988 | 79 | 0.020 |
Why?
|
| Diarrhea | 1 | 1987 | 181 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1987 | 127 | 0.020 |
Why?
|
| Counseling | 1 | 1988 | 174 | 0.020 |
Why?
|
| Informed Consent | 1 | 1988 | 281 | 0.010 |
Why?
|
| Stavudine | 1 | 2004 | 4 | 0.010 |
Why?
|
| Lamivudine | 1 | 2004 | 13 | 0.010 |
Why?
|
| Lopinavir | 1 | 2004 | 6 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2004 | 311 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2003 | 57 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2004 | 339 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 172 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 872 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 873 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1791 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1988 | 2480 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 983 | 0.010 |
Why?
|
| Feces | 1 | 1987 | 360 | 0.000 |
Why?
|